MX2019003970A - Péptidos de arginasa inmunogénicos. - Google Patents

Péptidos de arginasa inmunogénicos.

Info

Publication number
MX2019003970A
MX2019003970A MX2019003970A MX2019003970A MX2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A MX 2019003970 A MX2019003970 A MX 2019003970A
Authority
MX
Mexico
Prior art keywords
peptides
immunogenic
arginase
immunogenic arginase
fragments
Prior art date
Application number
MX2019003970A
Other languages
English (en)
Spanish (es)
Inventor
Hald Andersen Mads
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of MX2019003970A publication Critical patent/MX2019003970A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001Arginase (3.5.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019003970A 2016-10-07 2017-10-06 Péptidos de arginasa inmunogénicos. MX2019003970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16192794 2016-10-07
PCT/EP2017/075443 WO2018065563A1 (en) 2016-10-07 2017-10-06 Immunogenic arginase peptides

Publications (1)

Publication Number Publication Date
MX2019003970A true MX2019003970A (es) 2019-12-05

Family

ID=57123856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003970A MX2019003970A (es) 2016-10-07 2017-10-06 Péptidos de arginasa inmunogénicos.

Country Status (19)

Country Link
US (3) US10858642B2 (enExample)
EP (2) EP3522905B1 (enExample)
JP (1) JP7211938B2 (enExample)
KR (1) KR102674521B1 (enExample)
CN (1) CN109890399A (enExample)
AU (1) AU2017341112B2 (enExample)
CA (1) CA3039510A1 (enExample)
DK (1) DK3522905T3 (enExample)
ES (1) ES2992031T3 (enExample)
FI (1) FI3522905T3 (enExample)
HR (1) HRP20241486T1 (enExample)
HU (1) HUE069077T2 (enExample)
IL (1) IL265805B2 (enExample)
LT (1) LT3522905T (enExample)
MX (1) MX2019003970A (enExample)
PL (1) PL3522905T3 (enExample)
PT (1) PT3522905T (enExample)
SI (1) SI3522905T1 (enExample)
WO (1) WO2018065563A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674521B1 (ko) * 2016-10-07 2024-06-11 아이오 바이오테크 에이피에스 면역원성 아르기나제 펩타이드
GB201815549D0 (en) * 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
CA3250919A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps ARGINASE-2 BASED VACCINE
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) * 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
AU2002353934A1 (en) 2001-10-31 2003-05-12 Oxford Glycosciences (Uk) Ltd. Biomarkers of liver function
CA2586048C (en) * 2004-10-29 2014-03-11 Gregg A. Howe Protection against herbivores
SI3778885T1 (sl) 2008-10-31 2023-07-31 Aerase, Inc. Sestavki inženirskih humanih arginaz in metode za zdravljenje raka
US8679479B2 (en) * 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
CA2944554A1 (en) 2014-04-29 2015-11-05 Bio-Cancer Treatment International Limited Methods and compositions for modulating the immune system with arginase i
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102674521B1 (ko) * 2016-10-07 2024-06-11 아이오 바이오테크 에이피에스 면역원성 아르기나제 펩타이드
JP7312106B2 (ja) * 2016-10-27 2023-07-20 アイオー バイオテック エーピーエス 新しいpdl2化合物

Also Published As

Publication number Publication date
DK3522905T3 (da) 2024-10-21
HUE069077T2 (hu) 2025-02-28
US20190338270A1 (en) 2019-11-07
US20240167013A1 (en) 2024-05-23
US20210139877A1 (en) 2021-05-13
KR102674521B1 (ko) 2024-06-11
KR20190077381A (ko) 2019-07-03
AU2017341112B2 (en) 2024-06-27
ES2992031T3 (es) 2024-12-05
HRP20241486T1 (hr) 2025-01-03
CA3039510A1 (en) 2018-04-12
IL265805B2 (en) 2024-08-01
JP2019537562A (ja) 2019-12-26
IL265805B1 (en) 2024-04-01
LT3522905T (lt) 2024-11-11
SI3522905T1 (sl) 2025-02-28
FI3522905T3 (fi) 2024-10-31
EP3522905A1 (en) 2019-08-14
PT3522905T (pt) 2024-10-02
PL3522905T3 (pl) 2025-01-07
JP7211938B2 (ja) 2023-01-24
CN109890399A (zh) 2019-06-14
EP4406613A2 (en) 2024-07-31
EP3522905B1 (en) 2024-09-25
IL265805A (en) 2019-06-30
WO2018065563A1 (en) 2018-04-12
AU2017341112A1 (en) 2019-05-02
US11981944B2 (en) 2024-05-14
EP4406613A3 (en) 2024-10-23
US10858642B2 (en) 2020-12-08

Similar Documents

Publication Publication Date Title
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
ZA201904725B (en) Personalised immunogenic peptide identification platform
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
EP4218785A3 (en) Mitochondria-targeting peptides
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
MX361259B (es) Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
WO2014151369A3 (en) Stabilized ezh2 peptides
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
SG11201610947UA (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
PH12019500344A1 (en) Immunotherapy for polyomaviruses
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2017007740A (es) Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.
WO2016150415A8 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
AU2018275270A1 (en) Peptide PAC1 antagonists
ZA202201468B (en) Method